The trade deal that will overwrite the North American Free Trade Agreement awaits ratification by the U.S. Senate, but while the deal offers only 10 years of biotech data exclusivity, the agreement also forbids the practice of requiring sales and pricing data for products cleared or approved in the other two jurisdictions.